Bioequivalence Study of Sodium Divalproate Tablets 500 mg
Status:
Completed
Trial end date:
2019-02-12
Target enrollment:
Participant gender:
Summary
The objective of this study is to establish the bioequivalence of two valproic acid
formulations through the estimation of valproic acid in plasma samples, according to Food and
Drugs Administration (FDA), World Health Organization (WHO) and Colombian National Vigilance
Institute for Drugs and Food (INVIMA) guidelines.